@misc{oai:repo.qst.go.jp:00083859,
 author = {Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Zhang, Ming-Rong and Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Zhang, Ming-Rong},
 month = {Nov},
 note = {Objectives
Our goal is to develop a first-in-class cyclic peptide-based positron emission tomography (PET) tracer for imaging of uPA in cancers.

Methods
Three cyclic peptides (denoted as CAP-1 to 3) were labeled with Cu-64. PET imaging, ex vivo biodistribution, and histological examination were performed in mouse models bearing different types of tumors (glioma, breast, and colon) to evaluate the capacity and specificity of [64Cu]CAP-1/2/3 to target uPA in vivo.

Results
PET imaging with the three tracers in MC38 tumor-bearing mice perfectly delineated the expression level of uPA in the tumor tissues. Ex vivo biodistribution indicated that the tracers are majorly degraded in the liver and excreted out of the body through the kidney-bladder pathway.

Conclusion
We identified that cyclic peptide [64Cu]CPA-2 is a highly potential radiotracer for PET imaging of uPA in different kinds of tumors., 第61回日本核医学会学術総会},
 title = {Imaging urokinase plasminogen activator with a cyclic peptide-based PET tracer},
 year = {2021}
}